alk inhibitor nvl-655
alk inhibitor nvl-655: developed by 1 company · 3 clinical trials tracked.
alk inhibitor nvl-655 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could alk inhibitor nvl-655 → NUVL affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Nuvalent, Inc. (NUVL) Locally Advanced Solid Tumor; Non-small Cell Lung Cancer | Phase 3 |
Clinical Trials (3)
Expanded Access Treatment of Neladalkib (NVL-655) in Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)
Primary endpoint: Progression-free survival (PFS) per blinded independent central review (BICR)
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
Primary endpoint: Dose limiting toxicities (DLTs) (Phase 1)
Frequently asked questions
Who is developing alk inhibitor nvl-655?
alk inhibitor nvl-655 is being developed by Nuvalent, Inc..
How many clinical trials involve alk inhibitor nvl-655?
BioSniper tracks 3 clinical trials involving alk inhibitor nvl-655.